In short
This article summarizes clinical trials investigating the use of a pneumococcal vaccine containing pneumococcal polysaccharide serotype 6B conjugated to CRM197 and adsorbed on aluminium phosphate. The trials examine the vaccine's safety, immunogenicity, and effectiveness in various populations, including healthy adults, infants, and those at increased risk of pneumococcal disease. The studies aim to evaluate immune responses, compare different vaccine formulations, and assess the vaccine's ability to prevent pneumococcal infections.
At a glance
- Study Populations
- Healthy adults, infants, older adults (≥65 years), individuals at increased risk of pneumococcal disease
- Key Objectives
- Evaluate safety, immunogenicity, and effectiveness of pneumococcal vaccines containing serotype 6B
- Primary Outcomes
- Immune responses (antibody levels, OPA titers), adverse events, vaccine effectiveness against pneumococcal infections
- Secondary Outcomes
- Comparisons between vaccine formulations, co-administration effects, long-term protection
- Administration
- Intramuscular injection, single or multiple doses
- Safety Monitoring
- Adverse events, laboratory tests, vital signs
- Immunogenicity Measures
- Serotype-specific antibody levels, opsonophagocytic activity
- Effectiveness Endpoints
- Prevention of invasive pneumococcal disease, pneumonia, other pneumococcal infections
What is this vaccine?
This vaccine contains pneumococcal polysaccharide serotype 6B, which is a component that helps protect against infections caused by the bacteria Streptococcus pneumoniae (pneumococcus). Specifically, it targets serotype 6B of this bacteria.
The vaccine is part of a larger group called pneumococcal conjugate vaccines. These vaccines protect against multiple serotypes of pneumococcus bacteria. Some common brand names include Prevnar 13 and Apexxnar, which protect against 13 and 20 serotypes respectively.
How does it work?
The vaccine works by stimulating your immune system to produce antibodies against pneumococcal bacteria. Here's how:
- The vaccine contains parts of the bacterial outer coating (polysaccharides) for serotype 6B
- These polysaccharides are attached (conjugated) to a non-toxic protein called CRM197
- The combination helps your immune system recognize and respond better to the bacteria
- Your body produces antibodies that can fight off future infections from this serotype
The vaccine also contains aluminum phosphate as an adjuvant. This helps boost the immune response to make the vaccine more effective.
Who should get vaccinated?
Pneumococcal vaccines are recommended for:
- All children under 2 years old
- Adults 65 years and older
- People with certain medical conditions that increase risk of pneumococcal disease
- Smokers
Your doctor can advise if you should receive this vaccine based on your age, health status, and vaccination history.
How effective is it?
Studies have shown pneumococcal conjugate vaccines to be highly effective at preventing invasive pneumococcal disease caused by the serotypes included in the vaccine. For adults 65 and older, effectiveness against these serotypes is estimated to be over 75%.
One clinical trial is currently evaluating the effectiveness of a 20-valent pneumococcal conjugate vaccine (which includes serotype 6B) in preventing community-acquired pneumonia in adults 65 and older.
Is it safe?
Pneumococcal conjugate vaccines have been extensively studied and are considered very safe. They have been in use for over 20 years with millions of doses given worldwide.
However, like any medical treatment, there can be risks. Your healthcare provider can discuss if the benefits outweigh any potential risks for your specific situation.
Possible side effects
Most side effects are mild and go away on their own within a few days. Common side effects may include:
- Pain, redness, or swelling at the injection site
- Mild fever
- Fatigue
- Headache
- Muscle or joint pain
Serious allergic reactions are rare but possible with any vaccine. Seek immediate medical attention if you experience severe allergic symptoms after vaccination.
How is it given?
The vaccine is given as an injection, usually into the muscle of the upper arm or thigh. For most adults, a single dose is recommended. Some people may need additional doses based on their health status or previous vaccinations.
The typical dose is 0.5 mL. It's often given at the same time as other vaccines, like the flu shot.
Always follow your healthcare provider's recommendations for vaccination schedules and dosing.